Cross-Vendor Testing of HM-MRI

  • MVP2 was successfully implemented and tested to measure prostate tissue composition non-invasively from multiple MRI vendors.

 

  • Tested at multiple centers and multiple scanners

 

  • Philips 3T Achievaand Ingenia (UChicago) using endorectalcoil

 

  • SiemensSkyra3T (Ingalls Memorial Hospital, Flossmoor, IL) without endorectalcoil

 

  • HM-MRI metrics (tissue composition) were very similar for Philips and Siemens scanners and similar to those reported in literature.

 

  • Protocol validated using endorectalcoil or without it.  

 

  • Cancer is characterized by increased epithelium and reduced lumen in both cohorts with similar diagnostic accuracy (ROC analysis) for diagnosing cancer on Philips (AUC = 0.94-0.99),Siemens (AUC = 0.83-0.98).

 

  • We are currently validating HM-MRI on GEscanners.